Literature DB >> 23267106

Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives.

Joel R Meyerson1, Erin E H Tran, Oleg Kuybeda, Weizao Chen, Dimiter S Dimitrov, Andrea Gorlani, Theo Verrips, Jeffrey D Lifson, Sriram Subramaniam.   

Abstract

The extensive carbohydrate coat, the variability of protein structural features on HIV-1 envelope glycoproteins (Env), and the steric constraints of the virus-cell interface during infection, present challenges to the elicitation of effective full-length (~150 kDa), neutralizing antibodies against HIV. These hurdles have motivated the engineering of smaller antibody derivatives that can bind Env and neutralize the virus. To further understand the mechanisms by which these proteins neutralize HIV-1, we carried out cryoelectron tomography of native HIV-1 BaL virions complexed separately to two small (~15 kDa) HIV-neutralizing proteins: A12, which binds the CD4-binding site on Env, and m36, whose binding to Env is enhanced by CD4 binding. We show that despite their small size, the presence of these proteins and their effects on the quaternary conformation of trimeric Env can be visualized in molecular structures derived by cryoelectron tomography combined with subvolume averaging. Binding of Env to A12 results in a conformational change that is comparable to changes observed upon its binding to the CD4-binding site antibody, b12. In contrast, binding of Env to m36 results in an "open" quaternary conformation similar to that seen with binding of soluble CD4 or the CD4i antibody, 17b. Because these small neutralizing proteins are less sterically hindered than full-length antibodies at zones of virus-cell contact, the finding that their binding has the same structural consequences as that of other broadly neutralizing antibodies highlights their potential for use in therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23267106      PMCID: PMC3545814          DOI: 10.1073/pnas.1214810110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  Engineered antibodies.

Authors:  Peter J Hudson; Christelle Souriau
Journal:  Nat Med       Date:  2003-01       Impact factor: 53.440

2.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

Review 3.  Engineered antibody fragments and the rise of single domains.

Authors:  Philipp Holliger; Peter J Hudson
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

4.  Computer visualization of three-dimensional image data using IMOD.

Authors:  J R Kremer; D N Mastronarde; J R McIntosh
Journal:  J Struct Biol       Date:  1996 Jan-Feb       Impact factor: 2.867

5.  Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.

Authors:  C C LaBranche; T L Hoffman; J Romano; B S Haggarty; T G Edwards; T J Matthews; R W Doms; J A Hoxie
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype.

Authors:  J Dumonceaux; S Nisole; C Chanel; L Quivet; A Amara; F Baleux; P Briand; U Hazan
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

9.  Naturally occurring antibodies devoid of light chains.

Authors:  C Hamers-Casterman; T Atarhouch; S Muyldermans; G Robinson; C Hamers; E B Songa; N Bendahman; R Hamers
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

10.  Structural mechanism of trimeric HIV-1 envelope glycoprotein activation.

Authors:  Erin E H Tran; Mario J Borgnia; Oleg Kuybeda; David M Schauder; Alberto Bartesaghi; Gabriel A Frank; Guillermo Sapiro; Jacqueline L S Milne; Sriram Subramaniam
Journal:  PLoS Pathog       Date:  2012-07-12       Impact factor: 6.823

View more
  29 in total

1.  Reply to Subramaniam, van Heel, and Henderson: Validity of the cryo-electron microscopy structures of the HIV-1 envelope glycoprotein complex.

Authors:  Youdong Mao; Luis R Castillo-Menendez; Joseph G Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-05       Impact factor: 11.205

2.  Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.

Authors:  Weizao Chen; Yang Feng; Ponraj Prabakaran; Tianlei Ying; Yanping Wang; Jianping Sun; Camila D S Macedo; Zhongyu Zhu; Yuxian He; Victoria R Polonis; Dimiter S Dimitrov
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

3.  Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.

Authors:  Ming Sun; Craig S Pace; Xin Yao; Faye Yu; Neal N Padte; Yaoxing Huang; Michael S Seaman; Qihan Li; David D Ho
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-15       Impact factor: 3.731

Review 4.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

Review 5.  Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.

Authors:  Weizao Chen; Tianlei Ying; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2013-01-07       Impact factor: 4.388

6.  PRISM-EM: template interface-based modelling of multi-protein complexes guided by cryo-electron microscopy density maps.

Authors:  Guray Kuzu; Ozlem Keskin; Ruth Nussinov; Attila Gursoy
Journal:  Acta Crystallogr D Struct Biol       Date:  2016-09-20       Impact factor: 7.652

7.  Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission.

Authors:  Po-Jen Yen; Alon Herschhorn; Hillel Haim; Ignacio Salas; Christopher Gu; Joseph Sodroski; Dana Gabuzda
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

8.  Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.

Authors:  Yanling Wu; Jing Xue; Chunyu Wang; Wei Li; Lili Wang; Weizao Chen; Ponraj Prabakaran; Desheng Kong; Yujia Jin; Dan Hu; Yulu Wang; Cheng Lei; Diao Yu; Chao Tu; Ariola Bardhi; Igor Sidorov; Liying Ma; Harris Goldstein; Chuan Qin; Lu Lu; Shibo Jiang; Dimiter S Dimitrov; Tianlei Ying
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

9.  HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.

Authors:  Mangala Rao; Kristina K Peachman; Jiae Kim; Guofen Gao; Carl R Alving; Nelson L Michael; Venigalla B Rao
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

Review 10.  Correlative cryo-electron tomography and optical microscopy of cells.

Authors:  Peijun Zhang
Journal:  Curr Opin Struct Biol       Date:  2013-08-17       Impact factor: 6.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.